Immunotherapy before lung surgery shows promise in early trial
NCT ID NCT04205552
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested giving immunotherapy drugs (nivolumab alone or with relatlimab) for four weeks before surgery in 90 people with early-stage non-small cell lung cancer. The goal was to see if this approach is feasible and helps shrink tumors before removal. Results help determine the best drug combinations and immune responses.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NSCLC STAGE II are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Jessa Hospital Hasselt
Hasselt, Belgium
-
Netherlands Cancer Institute
Amsterdam, Netherlands
-
Thoraxklinik Heidelberg gGmbH-Universitätsklinikum Heidelberg
Heidelberg, 69126, Germany
-
University Hospital Essen
Essen, Germany
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Aiming to spare lung cancer patients from chemo: a smarter Pre-Surgery plan?
- New combo therapy aims to keep early lung cancer from returning
- Immunotherapy after surgery may keep early lung cancer at bay
- New drug combo aims to wipe out lung cancer before surgery
- New combo therapy aims to shrink lung tumors before surgery
- Chemo-Free combo shows promise in lung cancer trial